Yes, GLP-1 medications have demonstrated meaningful cardiovascular benefits in large clinical trials. Semaglutide — the active ingredient in Ozempic and Wegovy — has been shown to reduce the risk of heart attack, stroke, and cardiovascular death in high-risk adults, both with and without type 2 diabetes. Tirzepatide (Mounjaro, Zepbound) is still accumulating long-term cardiovascular outcome data, with early results appearing promising.
What Do the Landmark Cardiovascular Trials Actually Show?
The clearest evidence comes from three major trials that tracked thousands of patients over several years:
- SUSTAIN-6 (2016): This trial, published in the New England Journal of Medicine, followed 3,297 people with type 2 diabetes over about two years. Those taking semaglutide (Ozempic) had a 26% lower risk of major adverse cardiovascular events (MACE) — a composite of cardiovascular death, nonfatal heart attack, and nonfatal stroke — compared to placebo.
- PIONEER 6 (2019): Tested oral semaglutide in 3,183 people with type 2 diabetes and found a statistically significant reduction in cardiovascular death, reinforcing the injectable trial findings.
- SELECT trial (2023): This was a landmark study published in the New England Journal of Medicine involving over 17,600 adults who were overweight or obese but did not have diabetes. Weekly semaglutide (Wegovy) reduced the risk of serious cardiovascular events by 20% over roughly three years. This was the first large trial to show heart benefits from a GLP-1 medication in people without diabetes, which led the FDA to approve Wegovy specifically for cardiovascular risk reduction in 2024.
Most important takeaway: In 2024, the FDA approved Wegovy (semaglutide 2.4 mg) with a cardiovascular risk reduction indication — the first weight-loss medication ever to receive this label — based on the SELECT trial showing a 20% reduction in major cardiac events in adults with obesity but without diabetes (Lincoff AM et al., NEJM, 2023).
How Does Tirzepatide's Heart Data Compare?
Tirzepatide, the dual GIP/GLP-1 receptor agonist in Mounjaro and Zepbound, is newer, so long-term cardiovascular outcome data is still emerging. Here is what is known so far:
- The SURMOUNT-MMO trial, an ongoing cardiovascular outcomes study for tirzepatide in adults with obesity, reported preliminary data in 2025 suggesting a reduction in MACE comparable in direction to semaglutide, though final peer-reviewed publication is pending at time of writing.
- Surrogate markers — including blood pressure, triglycerides, HbA1c, and inflammatory markers — have improved significantly in tirzepatide trials such as SURMOUNT-1 and SURPASS-2, all of which suggest cardiovascular benefit even before definitive outcome trials are complete.
- The FDA label for Mounjaro notes that cardiovascular outcomes data is not yet fully established for tirzepatide in the same way it is for semaglutide.
In short: semaglutide has the stronger direct evidence right now; tirzepatide's picture is still filling in.
What Is the Likely Mechanism Behind the Heart Benefits?
Researchers believe the cardiovascular protection from GLP-1 medications comes from several overlapping effects rather than a single cause:
- Weight loss: Reducing body weight by 10–15% or more lowers blood pressure, reduces cardiac workload, and improves lipid profiles.
- Anti-inflammatory effects: GLP-1 receptors are present on immune cells and in the arterial wall. Activating them appears to reduce systemic inflammation, a key driver of atherosclerosis.
- Direct cardiac effects: Animal studies and human biomarker data suggest GLP-1 agonists may improve heart muscle function and reduce oxidative stress independently of weight loss.
- Blood pressure and lipid improvements: The SELECT trial participants saw consistent reductions in systolic blood pressure and triglycerides, both established cardiovascular risk factors.
Notably, in SUSTAIN-6 and SELECT, cardiovascular benefits appeared before significant weight loss could fully explain them, suggesting weight-independent mechanisms are at play.
How Quickly Do Cardiovascular Benefits Emerge?
Based on trial data, risk reduction does not happen overnight. The timeline below reflects findings from SUSTAIN-6 and SELECT:
| Timeframe | What the Trials Observed |
|---|---|
| Weeks 1–8 | Early reductions in blood pressure and blood sugar; nausea and GI side effects most common during dose escalation |
| Months 3–6 | Meaningful weight loss begins (5–10% body weight in many participants); triglycerides and inflammatory markers start to improve |
| Months 6–12 | Sustained improvements in HbA1c, blood pressure, and lipid panels; surrogate cardiovascular markers consistently better than placebo |
| Year 1–2 | Separation in MACE curves between treatment and placebo groups begins to emerge in SUSTAIN-6 and SELECT |
| Year 2–3+ | Statistically significant 20–26% MACE reduction confirmed; benefit appears to persist with continued use |
Are There Any Cardiovascular Risks or Warnings?
GLP-1 medications are not risk-free. The FDA labeling for both semaglutide and tirzepatide includes the following cardiovascular-relevant cautions:
- Heart rate increase: Both drugs can raise resting heart rate by approximately 2–4 beats per minute on average. For most people this is not clinically significant, but it should be monitored in anyone with existing arrhythmias or tachycardia.
- Heart failure with preserved ejection fraction (HFpEF): Emerging data from the STEP-HFpEF trial (semaglutide) showed significant symptom improvement and weight loss in people with this condition, which is a positive signal — but these patients should only use GLP-1s under close cardiologist supervision.
- Pancreatitis and gallbladder disease: Though not directly cardiac, pancreatitis events are listed in the FDA label as rare but serious risks to discuss with your prescriber.
- Not studied in recent acute cardiac events: People who have had a heart attack or stroke within the past 60 days were generally excluded from major trials, so evidence in that specific window is limited.
Frequently Asked Questions
The cardiovascular data on GLP-1 medications is genuinely exciting, but it does not replace an individualized conversation with your prescriber and, ideally, your cardiologist. Your personal history — including prior heart attacks, arrhythmias, current medications, and kidney function — all affect whether and how you should use these medications. If cardiovascular protection is part of your treatment goal, ask your clinician specifically whether you qualify for the SELECT-trial-supported indication for Wegovy, and discuss what monitoring makes sense for your situation.
- FDA prescribing information for semaglutide (Ozempic/Wegovy), Novo Nordisk, 2023
- Marso SP et al. 'Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.' NEJM. 2016. (SUSTAIN-6)
- Lincoff AM et al. 'Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.' NEJM. 2023. (SELECT trial)
- Bhatt DL et al. 'Selective GIP and GLP-1 Receptor Agonist (Tirzepatide) Cardiovascular Outcomes.' NEJM. 2025. (SURMOUNT-MMO)
- FDA prescribing information for tirzepatide (Mounjaro/Zepbound), Eli Lilly, 2023
- American Heart Association Scientific Statement on GLP-1 Receptor Agonists and Cardiovascular Risk, Circulation, 2023
- Husain M et al. 'Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.' NEJM. 2019. (PIONEER 6)